Clinical Scorecard: Less Burn, Less Bacteria in IVT Prep
At a Glance
| Category | Detail |
|---|---|
| Condition | Pre-intravitreal injection ocular surface antisepsis |
| Key Mechanisms | Use of chlorine dioxide aqueous solution (IRX-101) as an antiseptic with superior bactericidal activity and improved patient tolerance compared to povidone-iodine |
| Target Population | Patients undergoing intravitreal injections |
| Care Setting | Ophthalmology outpatient clinics and procedural settings |
Key Highlights
- IRX-101 (chlorine dioxide solution) shows greater efficacy against Staphylococcus epidermidis and Staphylococcus aureus than povidone-iodine in preclinical data.
- Clinical trials demonstrate IRX-101 is better tolerated by patients, causing significantly less burning sensation.
- Potential for IRX-101 to become an affordable and accessible alternative antiseptic for intravitreal injection preparation.
Guideline-Based Recommendations
Diagnosis
- Not applicable—focus is on antiseptic preparation prior to intravitreal injections.
Management
- Consider use of IRX-101 as a topical antiseptic agent for ocular surface preparation before intravitreal injections to reduce bacterial load and improve patient comfort.
Monitoring & Follow-up
- Monitor patient tolerance and any adverse reactions during and after antiseptic application.
Risks
- Potential unknown long-term safety profile of IRX-101; continued evaluation in clinical trials recommended.
Patient & Prescribing Data
Patients receiving intravitreal injections requiring ocular surface antisepsis
IRX-101 may reduce discomfort associated with antiseptic application while maintaining or improving antibacterial efficacy compared to povidone-iodine.
Clinical Best Practices
- Use antiseptic agents with proven bactericidal efficacy against common ocular pathogens prior to intravitreal injections.
- Consider patient comfort and tolerance when selecting antiseptic agents to improve compliance and experience.
- Stay informed on emerging clinical trial data regarding new antiseptic agents such as IRX-101.
References
- 2025 American Academy of Ophthalmology Annual Meeting - STERILE and RELIEF trials data
- Retinal Physician Video Channel Interview with Dr. David Brown
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
